User profiles for M. Miravitlles

Marc Miravitlles

Hospital Universitari Vall d'Hebron / Vall d'Hebron Institut de Recerca (VHIR). Barcelona
Verified email at separ.es
Cited by 43752

Epidemiology and costs of chronic obstructive pulmonary disease

…, A Jemal, TA Lee, M Miravitlles… - European …, 2006 - Eur Respiratory Soc
Worldwide, COPD is in the spotlight, since the high prevalence, morbidity and mortality
present challenges for healthcare systems. The inconsistent use of terminology for COPD, and …

Outcomes for COPD pharmacological trials: from lung function to biomarkers

…, DA Mahler, B Make, M Miravitlles… - European respiratory …, 2008 - Eur Respiratory Soc
The American Thoracic Society/European Respiratory Society jointly created a Task Force
on “Outcomes for COPD pharmacological trials: from lung function to biomarkers” to inform …

An official American Thoracic Society/European Respiratory Society statement: research questions in chronic obstructive pulmonary disease

…, DM Mannino, FJ Martinez, M Miravitlles… - American journal of …, 2015 - atsjournals.org
Background: Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity,
mortality, and resource use worldwide. The goal of this Official American Thoracic Society (…

Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study

M Miravitlles, M Ferrer, A Pont, R Zalacain… - Thorax, 2004 - thorax.bmj.com
Background: A study was undertaken to evaluate exacerbations and their impact on the
health related quality of life (HRQL) of patients with chronic obstructive pulmonary disease (…

Geographic variations in prevalence and underdiagnosis of COPD: results of the IBERPOC multicentre epidemiological study

VS Penña, M Miravitlles, R Gabriel, CA Jiménez-Ruiz… - Chest, 2000 - Elsevier
… In a survey on primary care in Spain, Miravitlles etal 15 found that only 47% of patients treated
and followedup because of chronic respiratory symptoms had spirometry performed. Inthe …

Health outcomes following treatment for 6 months with once daily tiotropium compared with twice daily salmeterol in patients with COPD

V Brusasco, R Hodder, M Miravitlles, L Korducki… - Thorax, 2006 - thorax.bmj.com
Background: A study was undertaken to record exacerbations and health resource use in
patients with COPD during 6 months of treatment with tiotropium, salmeterol, or matching …

Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities

M Miravitlles, JB Soriano, F Garcia-Rio, L Muñoz… - Thorax, 2009 - thorax.bmj.com
Aims: This study aimed to determine the prevalence of chronic obstructive pulmonary disease
(COPD) in Spain and identify the level of undiagnosed disease and its impact on health-…

Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD

M Miravitlles, C Espinosa, E Fernández-Laso… - Chest, 1999 - Elsevier
Study objectives To investigate the possible relationship between functional respiratory
impairment measured by FEV 1 and isolation of diverse pathogens in the sputum of patients with …

Symptom variability in patients with severe COPD: a pan-European cross-sectional study

…, MR Partridge, M Miravitlles, M Cazzola… - European …, 2011 - Eur Respiratory Soc
In between exacerbations, chronic obstructive pulmonary disease (COPD) is usually regarded
as a stable condition, but there is increasing recognition of variability in this state. This …

Management of COPD exacerbations: a European respiratory society/American thoracic society guideline

JA Wedzicha, M Miravitlles, JR Hurst… - European …, 2017 - Eur Respiratory Soc
… The initial draft of the manuscript was prepared by the co-chairs, methodologists and one
panellist (M. Miravitlles). The panel members wrote the content for the online supplement, …